Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries

BACKGROUND: Investing in late-stage clinical trials, trial sites, and production capacity for new health products could improve access to vaccines, therapeutics, and infectious disease diagnostics in middle-income countries. This study assesses the case for such investment in three of these countrie...

Descripción completa

Detalles Bibliográficos
Autores principales: Schäferhoff, Marco, Zimmerman, Armand, Diab, Mohamed M, Mao, Wenhui, Chowdhary, Vipul, Gill, Davinder, Karanja, Robert, Madikizela, Mziwandile, Ogbuoji, Osondu, Yamey, Gavin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210258/
https://www.ncbi.nlm.nih.gov/pubmed/35714631
http://dx.doi.org/10.1016/S2214-109X(22)00206-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210258/
https://www.ncbi.nlm.nih.gov/pubmed/35714631
http://dx.doi.org/10.1016/S2214-109X(22)00206-6

Ejemplares similares